According to Scynexis, preclinical studies have consistently demonstrated potent antifungal activity of SCY-247 across multiple efficacy models, along with extensive tissue distribution. The company has also reported positive phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) data, showing a favorable safety profile and pharmacokinetics. Notably, SCY-247 achieved target drug exposures for invasive fungal disease at lower doses than Scynexis’ first-generation antifungal candidate, supporting its potential as a differentiated therapy.
The FDA’s QIDP designation, established under the Generating Antibiotic Incentives Now (GAIN) Act, provides significant development incentives for antifungal and antibacterial drugs intended to treat serious or life-threatening infections. If approved, SCY-247 would be eligible for an additional five years of market exclusivity on top of existing exclusivity periods, resulting in at least 10 years of post-approval protection. The Fast Track designation further enables more frequent interactions with the FDA, eligibility for Accelerated Approval and Priority Review, and the possibility of rolling submission of a future New Drug Application.
What You Need to Know
FDA QIDP and Fast Track designations signal strong recognition of SCY-247’s potential and provide meaningful incentives to accelerate development.
SCY-247 has shown activity against highly resistant fungi, including Candida auris, a rapidly spreading global “superbug.”
SCYNEXIS plans multiple clinical milestones in 2026, including Phase 1 and Phase 2 studies and proof-of-concept data for invasive candidiasis.
Looking ahead, Scynexis plans to advance SCY-247 into the clinic in 2026, initiating a phase 1 study of an intravenous formulation and a phase 2 study of an oral formulation in invasive candidiasis. The company also expects to release proof-of-concept data for the oral formulation in the same year and continues to explore non-dilutive funding opportunities to support development.
With antifungal resistance increasingly viewed as a health security threat, Scynexis believes SCY-247’s broad-spectrum activity and novel profile position it as a promising candidate to help fill a critical gap in the antifungal treatment landscape.
Reference
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247. Scynexis press release. January 21, 2026. Accessed January 25, 2026.
https://ir.scynexis.com/news-events/press-releases/detail/356/scynexis-receives-fda-qualified-infectious-disease-product